阿托伐他汀联合稳心颗粒治疗阵发性房颤疗效观察

目的：探讨阿托伐他汀联合稳心颗粒治疗阵发性房颤的临床疗效。方法：随机选取阵发性房颤患者94例,分为治疗组（阿托伐他汀稳心颗粒组）和对照组（胺碘酮组）。治疗组口服阿托伐他汀联合稳心颗粒,对照组口服胺碘酮,随访12个月,观察两组的疗效。结果：治疗组窦性心律维持率高,房颤复发率明显下降（P〈0.05）,心功能明显改善（P〈0.05）,左室射血分数（LVEF）明显提高（P〈0.05）,左房内经（LAD）明显缩小（P〈0.05）,C反应蛋白（CRP）水平显著降低（P〈0.01）,与对照组比较,差异均有统计学意义。结论：阿托伐他汀联合稳心颗粒能更有效预防阵发性房颤复发。

Clinical observation of Atorvastatin combined with Wenxin Granules in the treatment of paroxysmal atrial fibrillation

Objective：To observe the effect of Atorvastatin combined with Wenxin Granules in the treatment of paroxysmal atrial fibrillation.Methods：94 paroxysmal atrial fibrillation patients were enrolled and randomly divided into treatment group and control group.The treatment group were treated with Atorvastatin and Wenxin Granules,and the control group only with Amiodarone.Followed up 12 months,we observed the effect of two groups.Results：Compared with the control group,the sinus rhythm maintenace rate in treatment group was higher,and the recurrence rate in treatment group was lower,heart function improved obviously,LVEF increased remarkably,LAD shrank obviously,CRP levels were lower,there were significant differences statistically in comparison between two groups.Conclusion：Atorvastatin combined with Wenxinkeli can be used to treat patients with paroxysmal atrial fibrillation and prevent the recurrence.